1
Robert M Gale, Victor Goetz, Eun S Lee, Lina T Taskovich, Su I Yum: Transdermal administration of fentanyl and device therefor. Alza Corporation, Steven F Stone, May 13, 1986: US04588580 (296 worldwide citation)

Transdermal delivery systems for delivery of fentanyl and its analgetically effective derivatives for extended periods of time are disclosed which deliver the base form of the drug at a rate of from 0.5 to 10 .mu.g/cm.sup.2 /hr for a substantial portion of their useful life. The systems can be from ...


2
Harold M Leeper, Diane Nedberge, Lina T Taskovich: Skin permeation enhancer compositions. Alza Corporation, Steven F Stone, Paul L Sabatine, Edward L Mandell, February 4, 1986: US04568343 (211 worldwide citation)

A method for enhancing the transdermal flux of a transdermally deliverable drug through intact skin is described in which the drug is delivered simultaneously with polyethylene glycol monolaurate. Preferred embodiments of transdermal therapeutic systems for delivering drug and polyethylene glycol mo ...


3
Jessica A Warring, David B Swedlow, Michael J N Cormier, Su Il Yum, Lina T Taskovich, Albert Ollerdessen: Methods and devices for facilitated non-invasive oxygen monitoring. ALZA Corporation, Alisa A Harbin, Steven F Stone, Edward L Mandell, April 4, 1995: US05402777 (134 worldwide citation)

The present invention is directed to a sensor system for use with a blood characteristic measurement device such as a pulse oximeter, on areas of the body having low normal cutaneous blood flow and for monitoring a blood characteristic such as oxygen saturation and pulse rate of patients, preferably ...


4
Lina T Taskovich: Skin permeation enhancer compositions using glycerol monooleate. ALZA Corporation, Shelley G Precivale, Edward L Mandell, Steven F Stone, September 5, 1989: US04863738 (70 worldwide citation)

A method for enhancing the flux of transdermally deliverable drugs through intact skin is described in which the drug is delivered simultaneously with glycerol monooleate. Preferred embodiments of therapeutic systems for delivering drug and glycerol monooleate employ matrix containing drug at a conc ...


5
Terry L Burkoth, Lina T Taskovich, Nieves Crisologo: Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate. Alza Corporation, Michael J Rafa, Paul L Sabatine, Steven F Stone, July 28, 1998: US05785991 (47 worldwide citation)

Compositions, devices, and methods for transdermal administration of an active agent are disclosed using a novel dual permeation enhancer mixture comprising lauryl acetate and a monoglyceride, preferably glycerol monolaurate. The dual permeation enhancer mixture comprising lauryl acetate is a potent ...


6
Terry L Burkoth, Lina T Taskovich, Russell D Beste, Robert M Gale, Eun Soo Lee, Richard D Hamlin, Su LL Yum: Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate. ALZA Corporation, Michael J Rafa, Steve F Stone, December 1, 1998: US05843468 (45 worldwide citation)

Compositions, devices, and methods for transdermal administration of an active agent are disclosed using a novel dual permeation enhancer mixture comprising lauryl acetate and a monoglyceride, preferably glycerol monolaurate. The dual permeation enhancer mixture comprising lauryl acetate is a potent ...


7
Robert M Gale, Eun Soo Lee, Lina T Taskovich, Terry L Burkoth: Oxybutynin transdermal device having decreased delamination. ALZA Corporation, Michael J Rafa, Paul L Sabatine, Steven F Stone, March 25, 1997: US05614211 (11 worldwide citation)

A device for the transdermal administration of oxybutynin comprising a microporous tie layer located between the oxybutynin reservoir and the contact adhesive. The tie layer eliminates blooming and delamination and has no appreciable adverse effect on either the oxybutynin flux or release rate from ...


8
F Eugene Yates, Lina T Taskovich, Su I Yum, Nieves M Crisologo: Controlled transdermal administration of melatonin. ALZA Corporation, Michael J Rafa, Steven F Stone, Edward L Mandell, April 16, 1996: US05508039 (9 worldwide citation)

The present invention is directed to the transdermal administration of melatonin together with a suitable permeation enhancer. The invention includes a transdermal drug delivery device (10) comprising a matrix (12) adapted to be placed in melatonin- and permeation enhancer-transmitting relation with ...